MEA Left Ventricular Assist Device (LVAD) Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 58
1.1 OBJECTIVES OF THE STUDY 58
1.2 MARKET DEFINITION 58
1.3 OVERVIEW OF MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET 58
1.4 LIMITATIONS 61
1.5 MARKETS COVERED 61
2 MARKET SEGMENTATION 65
2.1 MARKETS COVERED 65
2.2 GEOGRAPHICAL SCOPE 66
2.3 YEARS CONSIDERED FOR THE STUDY 67
2.4 CURRENCY AND PRICING 67
2.5 DBMR TRIPOD DATA VALIDATION MODEL 68
2.6 MULTIVARIATE MODELLING 71
2.7 PRODUCT TYPE LIFELINE CURVE 71
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 72
2.9 DBMR MARKET POSITION GRID 73
2.10 MARKET END USER COVERAGE GRID 74
2.11 VENDOR SHARE ANALYSIS 75
2.12 SECONDARY SOURCES 76
2.13 ASSUMPTIONS 76
3 EXECUTIVE SUMMARY 77
4 PREMIUM INSIGHTS 80
4.1 PESTEL 82
4.2 PORTER'S 83
4.3 INDUSTRIAL INSIGHTS: 84
5 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: REGULATIONS 85
5.1 REGULATION IN U.S. 85
5.1.1 GUIDELINES- 85
5.2 REGULATION IN EUROPE 86
5.2.1 GUIDELINES FOR THE MANUFACTURERS: 86
5.3 REGULATION IN CANADA 86
5.3.1 GUIDELINES FOR THE MANUFACTURERS: 86

5.4 REGULATION IN MEXICO 87
5.4.1 GUIDELINES FOR THE MANUFACTURERS: 87
6 MARKET OVERVIEW 88
6.1 DRIVERS 90
6.1.1 INCREASING GERIATRIC POPULATION ALONG WITH RISING PREVALENCE OF CARDIAC DISEASES 90
6.1.2 PRESENCE OF FAVOURABLE REIMBURSEMENT POLICIES 91
6.1.3 CHANGING LIFESTYLE TRIGGERS THE DEVELOPMENT OF CARDIOVASCULAR DISEASES 91
6.2 RESTRAINTS 92
6.2.1 HIGH COST OF LVAD IMPLANTATION AND TREATMENT 92
6.2.2 COMPLICATIONS AND RISKS ASSOCIATED WITH LVAD 93
6.3 OPPORTUNITIES 93
6.3.1 INCREASE IN HEALTHCARE EXPENDITURE 93
6.3.2 INCREASE IN MINIMALLY INVASIVE PROCEDURE 94
6.3.3 INCREASING SHORTAGE OF ORGAN DONORS 94
6.3.4 TECHNOLOGICAL ADVANCEMENTS IN LEFT VENTRICULAR ASSIST DEVICES 95
6.4 CHALLENGES 95
6.4.1 ONGOING COVID-19 95
6.4.2 INCREASE IN PRODUCT RECALL 96
7 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY PRODUCT TYPE 97
7.1 OVERVIEW 98
7.2 HEART PUMP 101
7.3 CONTROLLER 101
7.4 BATTERIES 102
7.4.1 RECHARGEABLE 103
7.4.2 NON-RECHARGEABLE 103
7.5 WIRES 103
8 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY THERAPY 105
8.1 OVERVIEW 106
8.2 BRIDGE-TO-TRANSPLANT (BTT) THERAPY 109
8.2.1 HEART PUMP 110
8.2.2 CONTROLLER 110
8.2.3 BATTERIES 110
8.2.4 WIRES 110

8.3 DESTINATION THERAPY 110
8.3.1 HEART PUMP 111
8.3.2 CONTROLLER 111
8.3.3 BATTERIES 112
8.3.4 WIRES 112
8.4 BRIDGE-TO-CANDIDACY (BTC) THERAPY 112
8.4.1 HEART PUMP 113
8.4.2 CONTROLLER 113
8.4.3 BATTERIES 113
8.4.4 WIRES 114
8.5 BRIDGE-TO-RECOVERY (BTR) THERAPY 114
8.5.1 HEART PUMP 115
8.5.2 CONTROLLER 115
8.5.3 BATTERIES 115
8.5.4 WIRES 115
9 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY AGE GROUP 116
9.1 OVERVIEW 117
9.2 ADULT 120
9.2.1 19-39 YEARS 121
9.2.2 40-59 YEARS 121
9.2.3 60-79 YEARS 121
9.2.4 ABOVE 80 YEARS 121
9.3 PEDIATRIC 121
10 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY GENERATION 123
10.1 OVERVIEW 124
10.2 SECOND GENERATION DEVICES 127
10.3 THIRD GENERATION DEVICES 127
10.4 FIRST GENERATION DEVICES 128
11 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY DESIGN 130
11.1 OVERVIEW 131
11.2 AXIAL 134
11.3 CENTRIFUGAL 134
12 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY INDICATION 136
12.1 OVERVIEW 137
12.2 CONGESTIVE HEART FAILURE 140
12.2.1 HEART PUMP 141
12.2.2 CONTROLLER 141
12.2.3 BATTERIES 141
12.2.4 WIRES 141
12.3 CONGENITAL HEART DISEASE 141
12.3.1 HEART PUMP 142
12.3.2 CONTROLLER 142
12.3.3 BATTERIES 142
12.3.4 WIRES 143
12.4 MYOCARDITIS 143
12.4.1 HEART PUMP 144
12.4.2 CONTROLLER 144
12.4.3 BATTERIES 144
12.4.4 WIRES 144
12.5 CARDIAC ARREST 144
12.5.1 HEART PUMP 145
12.5.2 CONTROLLER 145
12.5.3 BATTERIES 146
12.5.4 WIRES 146
12.6 FAMILIAL ARRHYTHMIAS AND ARRHYTHMIC CARDIOMYOPATHIES 146
12.6.1 HEART PUMP 147
12.6.2 CONTROLLER 147
12.6.3 BATTERIES 147
12.6.4 WIRES 148
12.7 ADVANCED HEART FAILURE 148
12.7.1 HEART PUMP 149
12.7.2 CONTROLLER 149
12.7.3 BATTERIES 149
12.7.4 WIRES 149
12.8 OTHERS 149

13 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY DURABILITY 151
13.1 OVERVIEW 152
13.2 LONG-TERM 155
13.3 INTERMEDIATE-TERM 155
13.4 SHORT-TERM 156
14 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY PULSE TYPE 158
14.1 OVERVIEW 159
14.2 NONPULSATILE 162
14.3 PULSATILE 162
15 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY END USER 164
15.1 OVERVIEW 165
15.2 HOSPITAL 168
15.3 CARDIAC CATH LABORATORIES 168
15.4 SPECIALTY CLINICS 169
15.5 OTHERS 170
16 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) DISEASE MARKET, BY DISTRIBUTION CHANNEL 172
16.1 OVERVIEW 173
16.2 DIRECT TENDER 176
16.3 RETAIL SALES 176
16.4 OTHERS 177
17 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET, BY REGION 178
17.1 MIDDLE EAST & AFRICA 179
17.1.1 SAUDI ARABIA 191
17.1.2 SOUTH AFRICA 197
17.1.3 U.A.E. 204
17.1.4 EGYPT 211
17.1.5 ISRAEL 218
17.1.6 REST OF MIDDLE EAST & AFRICA 224
18 MIDDLE EAST & AFRICA LEFT VENTRICULAR ASSIST DEVICE (LVAD) MARKET: COMPANY LANDSCAPE 225
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 225
19 SWOT ANALYSIS 226
20 COMPANY PROFILE 227
20.1 ABIOMED 227
20.1.1 COMPANY SNAPSHOT 227
20.1.2 REVENUE ANALYSIS 227
20.1.3 COMPANY SHARE ANALYSIS 228
20.1.4 PRODUCT PORTFOLIO 228
20.1.5 RECENT DEVELOPMENTS 229
20.1.5.1 FDA APPROVAL 229
20.1.5.2 FDA APPROVAL 229
20.2 ABBOTT 230
20.2.1 COMPANY SNAPSHOT 230
20.2.2 REVENUE ANALYSIS 230
20.2.3 COMPANY SHARE ANALYSIS 231
20.2.4 PRODUCT PORTFOLIO 231
20.2.5 RECENT DEVELOPMENTS 231
20.2.5.1 SUPPLY INCREMENT 231
20.2.5.2 BREAK THROUGH DEVICE DESIGNATION 232
20.3 BERLIN HEART 233
20.3.1 COMPANY SNAPSHOT 233
20.3.2 COMPANY SHARE ANALYSIS 233
20.3.3 PRODUCT PORTFOLIO 234
20.3.4 RECENT DEVELOPMENT 234
20.3.4.1 PRODUCT APPROVAL 234
20.4 SAFT (A SUBSIDIARY OF TOTALENERGIES) 235
20.4.1 COMPANY SNAPSHOT 235
20.4.2 REVENUE ANALYSIS 235
20.4.3 COMPANY SHARE ANALYSIS 236
20.4.4 PRODUCT PORTFOLIO 236
20.4.5 RECENT DEVELOPMENT 236
20.4.5.1 PARTNERSHIP 236

20.5 JARVIK HEART, INC. 237
20.5.1 COMPANY SNAPSHOT 237
20.5.2 COMPANY SHARE ANALYSIS 237
20.5.3 PRODUCT PORTFOLIO 237
20.5.4 RECENT DEVELOPMENT 238
20.5.4.1 FDA APPROVAL 238
20.6 CORWAVE SA 239
20.6.1 COMPANY SNAPSHOT 239
20.6.2 PRODUCT PORTFOLIO 239
20.6.3 RECENT DEVELOPMENT 239
20.6.3.1 EXPANSION 239
20.7 EVAHEART, INC 240
20.7.1 COMPANY SNAPSHOT 240
20.7.2 PRODUCT PORTFOLIO 240
20.7.3 RECENT DEVELOPMENT 240
20.7.3.1 PRODUCT TRIAL 240
21 QUESTIONNAIRE 241
22 RELATED REPORTS 246